✉ Email this page to a colleague
« Back to Dashboard
ODM-201 is an investigational drug.
There have been 47 clinical trials for ODM-201. The most recent clinical trial was a Phase 3 trial, which was initiated on May 5th 2017.
The most common disease conditions in clinical trials are Prostatic Neoplasms, Parkinson Disease, and Motor Neuron Disease. The leading clinical trial sponsors are Orion Corporation, Orion Pharma, Bayer, and National Cancer Institute (NCI).
There are twenty-one US patents protecting this investigational drug and three hundred and seventeen international patents.
Recent Clinical Trials for ODM-201
|Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score||National Cancer Institute (NCI)||Phase 3|
|Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score||NRG Oncology||Phase 3|
|Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer||Bayer||Phase 2|
Top disease conditions for ODM-201
Top clinical trial sponsors for ODM-201
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|ODM-201||See Plans and Pricing||Carboxamide derivative and its diastereomers in stable crystalline form||Orlon Corporation (Espoo, FI)||See Plans and Pricing|
|ODM-201||See Plans and Pricing||Androgen receptor modulating compounds||ORION CORPORATION (Espoo, FI)||See Plans and Pricing|
|ODM-201||See Plans and Pricing||Process for the preparation of androgen receptor antagonists and intermediates thereof||Orion Corporation (Espoo, FI)||See Plans and Pricing|
|ODM-201||See Plans and Pricing||Compositions and methods for treatment of prostate cancer||California Institute of Technology (Pasadena, CA)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|ODM-201||European Patent Office||EP3250554||2035-01-30||See Plans and Pricing|
|ODM-201||Japan||JP2018503662||2035-01-30||See Plans and Pricing|
|ODM-201||Japan||JP2021020935||2035-01-30||See Plans and Pricing|
|ODM-201||World Intellectual Property Organization (WIPO)||WO2016120530||2035-01-30||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|